Fuhong Hanlius LAG-3 monoclonal antibody completed the first subject administration

On October 12, Henlius announced that its self-developed recombinant humanized anti-LAG-3 humanized monoclonal antibody injection HLX26 for the treatment of solid tumors and lymphoma in the phase 1 clinical study is in China (excluding Hong Kong, Macao and Taiwan).

HLX26 is an innovative humanized monoclonal antibody targeting the extracellular domain of Lymphocyte-activationgene3 (LAG-3) independently developed by Henlius, and is intended to be used in the treatment of solid tumors and lymphomas

LAG-3 is mainly expressed on activated T cells and some NK cells, and has a negative regulatory effect on the cell proliferation, activation and homeostasis of T cells

Preclinical pharmacological studies, pharmacokinetic studies and safety evaluation have proved that HLX26 has anti-tumor effects in vivo and in vitro, and has good tolerability and safety

This study is an open, dose escalation, first phase I human clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of HLX26 in patients with advanced/metastatic solid tumors or lymphomas

According to the Insight database, there are currently 8 types of LAG-3 in development in China, all of which are in early stage research and development, with the highest progress to clinical phase 2, and no similar products have been approved globally

LAG-3 monoclonal antibody target competition details (Insight)

From: Insight database (http://db.